Clinical Trial Update: PET Imaging Study of 89Zr-DFO-YS5 in Men With Prostate Cancer [Phase 1]

View source ↗

Summary

Phase 1 PET imaging study evaluating 89Zr-DFO-YS5 in men with prostate cancer, including metastatic castration-resistant disease; the trial is active but not re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• 89Zr-DFO-YS5

Snippet

Sponsor: Robert Flavell, MD, PhD | Conditions: Prostate Cancer, Metastatic Castration-resistant Prostate Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING